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Abstract  
Introduction: To date, little is known about the clinical features of pediatric COVID-19 patients admitted to 
intensive care units (ICUs).  
Objective: Herein, we aimed to describe the differences in demographic characteristics, laboratory findings, 
clinical presentations, and outcomes of Iranian pediatric COVID-19 patients admitted to ICU versus those in 
non-ICU settings.  
Methods: This multicenter investigation involved 15 general and pediatrics hospitals and included cases with 
confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on positive real-
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time reverse transcription polymerase chain reaction (RT-PCR) admitted to these centers between March and 
May 2020, during the initial peak of the COVID-19 pandemic in Iran.  
Results: Overall, 166 patients were included, 61 (36.7%) of whom required ICU admission. The highest 
number of admitted cases to ICU were in the age group of 1–5 years old. Malignancy and heart diseases were 
the most frequent underlying conditions. Dyspnea was the major symptom for ICU-admitted patients. There 
were significant decreases in PH, HCO3 and base excess, as well as increases in creatinine, creatine 
phosphokinase (CPK), lactate dehydrogenase (LDH), and potassium levels between ICU-admitted and non-ICU 
patients. Acute respiratory distress syndrome (ARDS), shock, and acute cardiac injury were the most common 
features among ICU-admitted patients. The mortality rate in the ICU-admitted patients was substantially 
higher than non-ICU cases (45.9% vs. 1.9%, respectively; p<0.001). 
Conclusions: Underlying diseases were the major risk factors for the increased ICU admissions and mortality 
rates in pediatric COVID-19 patients. There were few paraclinical parameters that could differentiate between 
pediatrics in terms of prognosis and serious outcomes of COVID-19. Healthcare providers should consider 
children as a high-risk group, especially those with underlying medical conditions. 
Key words: COVID-19; Intensive Care Units; Pediatric; Respiratory Tract Infections; SARS-CoV-2 
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INTRODUCTION
The current Coronavirus Disease 2019 (COVID-19) 
pandemic caused by the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) generally 
causes mild to moderate respiratory tract infection 
in humans. Patients usually recover without any 
special treatment. However, older people and 
especially those with underlying medical 
conditions are at an increased risk of developing 
severe disease outcomes (1, 2). 
Several studies on COVID-19 infection among 
pediatric patients have revealed differences in 
clinical signs and symptoms, prevalence rates, and 
mortality rates compared to adults (3, 4). Children 
are less affected by SARS-CoV-2 compared to older 
individuals in terms of the number of infected 
persons and the incidence of serious adverse 
outcomes (5, 6). Based on the results of previous 
epidemiological investigations, the prevalence of 
children affected by COVID-19 was 2.2% and 1.7% 
in China and the USA, respectively (4, 7). SARS-CoV-
2 is transmitted among the pediatric population 
mainly through direct contact, contaminated 
droplets, and perhaps aerosols (8, 9).  
Like adults, children can also experience a severe 
form of COVID-19 infection, leading to intensive 
care unit (ICU) admission. In previous studies, ICU 
admission rate among children with COVID-19 
varied from 1.7% to 16% (7, 10-12). However, the 
rate was lower than that reported for adults 
(ranged from 5% to 32%) (13-17). To date, limited 
studies have been carried out to characterize the 
clinical, laboratory, and demographic features of 
pediatric COVID-19 patients in Iran (18-21). 
Among four studies reporting epidemiological and 
clinical data of pediatric patients with COVID-19 
infection, the largest sample size was 35 cases in 
the survey conducted by Mahmoudi et al. (19).  
Herein, we aimed to conduct a multicenter study to 
compare demographic characteristics, laboratory 
findings, clinical features, and outcomes between 
pediatric COVID-19 patients admitted to the ICU 
versus non-ICU cases.  
Methods 
Study design, setting, and participants 
The current survey was a retrospective cross-
sectional study carried out on pediatric patients 
diagnosed with COVID-19 who were admitted to 15 
general and pediatrics hospitals in collaboration 
with the Iranian Network for Research in Viral 
Diseases (INRVD) between March 19th and May 
31th 2020. Overall results have been submitted 
elsewhere (under revision) (22). A portion of this 
population, whose COVID-19 was confirmed via 
positive real-time reverse transcription 
polymerase chain reaction (RT-PCR) result for 
SARS-CoV-2 according to World Health 
Organization (WHO) interim guidance (15), was 
selected for further analysis (n= 166).   
The major inclusion criteria were: patients who 
needed ventilation support either invasive 
mechanical ventilation or extra corporeal 
membrane oxygenation (ECMO) and/or organ 
dysfunction development who were transferred to 
the ICU.  
All other patients were transferred to wards for 
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specialist care and were included as non-ICU cases. 
This study was approved by the Institutional 
Review Board of Tehran University of Medical 
Sciences (Ethics code number: 1399.378). Written 
informed consent was obtained from parents of 
pediatric patients. 
Molecular detection of SARS-CoV-2 
Throat and nasal samples were obtained using 
flocked swabs immediately after admission. 
Laboratory confirmation of the SARS-CoV-2 was 
made using the RT-PCR assay (15). RT-PCR was 
carried out using the diagnostic kits approved by 
the Iranian Pasteur Institute, targeting the E and 
RdP genes, in line with the protocol of all 
laboratories across the country. The samples were 
deemed positive if the cycle thresholds (Ct) value 
was ≤ 37 and negative if the Ct value was > 40. 
Samples with a Ct value between 37–40 were 
considered to have a borderline result and their 
tests were repeated.  
Laboratory and imaging indicators  
Laboratory examinations including routine blood 
tests, hematological and biochemical tests, and 
assessment of biomarkers for monitoring lung, 
liver, and renal functions along with blood 
saturation parameters were performed in 
hospitals' laboratories. In line with the guidelines 
issued by The Ministry of Health, all confirmed 
COVID-19 cases with any respiratory symptoms 
underwent a chest X-ray upon admission. A chest 
CT scan was usually performed in the case of either 
the presence of any abnormality in their X-ray or 
for patients who developed the severe form of the 
disease. 
Data collection 
The epidemiological and demographic data, 
comorbidities, clinical symptoms, and signs on 
admission of all laboratory-confirmed COVID-19 
pediatric patients were retrospectively extracted 
from electronic medical records, using predefined 
standardized data collection forms provided by 
INRVD.  
Statistical analysis 
Statistical analyses were performed using R 
software (R Foundation for Statistical Computing, 
Vienna, Austria; http://cran.r-project.org/). 
Continuous variables were presented as mean 
±standard deviation (SD), and categorical variables 
were expressed as counts (%). Fisher's exact test 
and chi-square test of independence were used to 
compare categorical variables, and student t test 
was used for continuous variables. For 
comparative analyses, a P-value less than 0.05 was 
considered statistically significant. 
RESULTS 
Demographic characteristics and associated 
comorbidities 
A total of 325 cases were studied. Table 1 presents 
demographic characteristics and related 
comorbidities of pediatric patients with COVID-19 
on hospital admission. Out of the 166 studied 
patients, 61 (36.7%) were admitted to ICU, and 105 
(63.3%) were non-ICU cases. Based on the age 
group, the highest and the lowest numbers of 
admitted cases to ICU were in the age groups of 1–
5 and 5-10 years, respectively (31.1% vs 14.7%, 
p=0.025). The mean age (±SD) of all patients was 
79±64 months, and patients admitted to the ICU 
had a significantly lower age compared to non-ICU 
patients (63±63 vs. 88±64 months, respectively; 
p=0.004). Males were more affected in both ICU 
and non-ICU settings compared to the females 
(62.8% vs. 37.1% and 59.0% vs. 40.9%, 
respectively, p=0.704). Malignancies and heart 
diseases were the most common underlying 
conditions; each affecting 11.4% of ICU-admitted 
patients. 21.3% of ICU-admitted patients and 
39.0% of non-ICU patients had history of antibiotic 
use (p=0.029). However, there were no significant 
differences in influenza vaccination history, 
corticosteroid therapy, and chemotherapy 
between the two groups.  
Clinical characteristics 
The most common respiratory symptoms were 
cough (n=89; 53.6%), dyspnea (n=59; 35.5%), sore 
throat (n=7; 4.2%), and rhinorrhea (n=3; 1.8%). 
Sixty (36.1%) children had neurological symptoms 
including fatigue (n=27; 16%), drowsiness/loss of 
consciousness (n=9; 5.4%), seizure (n=11; 6.6%), 
headache (n=10; 6.0%), and myalgia (n=3; 1.8%). 
Nausea/vomiting (n=55; 33.1%), anorexia (n=42; 
25.3%), diarrhea (n=30; 18%), and abdominal pain 
(n=9; 5.4%) were the main gastrointestinal 
manifestations. 
Fever and cough were the most frequent clinical 
symptoms among both groups. However, dyspnea 
was more prevalent among ICU patients compared 
to non-ICU cases (50.8% vs. 26.6%, respectively, 
p=0.003, Table 1). Signs such as grunting (11% vs. 
1.9%) and nasal flaring (26% vs 2.9%) were more 
frequently seen in ICU cases versus non-ICU 
patients (p=0.013 and p<0.001, respectively, Table 
2). 
ARDS (n=19; 11.4%), nasal flaring (n=19; 11.4%), 
and wheezing (n=18; 10.8%) were the most 
common clinical signs among all patients. Among 
the list of complications, ARDS (28% vs 1.9%), 
shock (9.8% vs 2.9%) and acute cardiac injury 
(6.6% vs 0%) were the most important features  
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 Table 1: Demographic characteristics and associated comorbidities of pediatric patients with COVID-19 in all subjects and intensive 
care unit (ICU) versus non-ICU cases 
Admission detail 
Overall (n= 166) Non-ICU (n=105) ICU (n=61) 
P-value 
N (%) 
Age group (Year) 
0.025* 
0-1 28 (16.8) 11 (10.4) 17 (27.8) 
1-5 53 (31.9) 34 (32.3) 19 (31.1) 
5-10 26 (15.6) 17 (16.3) 9 (14.7) 
10-15 56 (33.7) 41 (39.0) 15 (24.5) 
Gender 
0.704 Male 102 (61.4) 66 (62.8) 36 (59.0) 
Female 64 (38.5) 39 (37.1) 25 (40.9) 
Associated comorbidities 
Asthma 4 (2.4) 3 (2.8) 1(1.6) 
<0.001* 
Cystic fibrosis  1 (0.6) 1 (0.9) 0 (0.0) 
Chronic kidney disease 4 (2.4) 1 (0.9) 3 (4.9) 
Diabetes 1 (0.6) 1 (0.9) 0 (0.0) 
Failure to thrive 4 (2.4) 2 (1.9) 2 (3.2) 
Heart diseases 9 (5.4) 2 (1.9) 7 (11.4) 
Immune suppression 2 (1.2) 0 (0.0) 2 (3.2) 
Malignancy 20 (12.0) 13 (12.3) 7 (11.4) 
Other 24 (14.4) 7 (6.6) 17 (27.8) 
No comorbidity 97 (58.4) 75 (71.4) 22 (36.0) 
Patient history 
Antibiotic use 54 (32.5) 41 (39.0) 13 (21.3) 0.029* 
Flu vaccination 22 (13.2) 13 (12.3) 9 (14.7) 0.805 
Corticosteroid therapy 16 (9.6) 9 (8.5) 7 (11.4) 0.706 
Chemotherapy 15 (9.0) 9 (8.5) 6 (9.8) 0.999 
 
Table 2: Clinical characteristics and outcomes of pediatric patients with COVID-19 in total population, intensive care unit (ICU)-
admitted, and non-ICU cases 
Admission details 




Fever 122 (73.4) 81 (77.1) 41 (67.2) 0.201 
Fatigue 27 (16.2) 19 (18.0) 8 (13.1) 0.504 
Cough 89 (53.6) 59 (56.1) 30 (49.1) 0.506 
Anorexia 42 (25.3) 26 (24.7) 16 (26.2) 0.999 
Dyspnea 59 (35.5) 28 (26.6) 31 (50.8) 0.003* 
Sore throat 7 (4.2) 6 (5.7) 1 (1.6) 0.402 
Diarrhea 30 (18.0) 18 (17.1) 12 (19.6) 0.805 
Nausea/Vomiting 55 (33.1) 37 (35.2) 18 (29.5) 0.603 
Headache 10 (6.0) 10 (9.5) 0 (0.0) 0.014* 
Abdominal pain 9 (5.4) 7 (6.6) 2 (3.2) 0.501 
Myalgia 3 (1.8) 3 (2.8) 0 (0.0) 0.306 
Rhinorrhea 3 (1.8) 2 (1.9) 1 (1.6) 0.999 
Drowsiness/Loss of consciousness 9 (5.4) 2 (1.9) 7 (11.4) 0.013* 
Seizures 11 (6.6) 4 (3.8) 7 (11.4) 0.100 
Skin rash 6 (3.6) 4 (3.8) 2 (3.2) 0.999 
Clinical signs 
Cyanosis 7 (4.2) 2 (1.9) 5 (8.1) 0.100 
Grunting 9 (5.4) 2 (1.9) 7 (11.4) 0.013* 
Nasal flaring 19 (11.4) 3 (2.8) 16 (26.2) <0.001* 
Wheezing 18 (10.8) 9 (8.8) 9 (14.7) 0.301 
Respiratory fine crackles 30 (18.0) 15 (14.2) 15 (24.5) 0.150 
Respiratory Coarse Crackles 21 (12.6) 12 (11.4) 9 (14.7) 0.703 
Shock 9 (5.4) 3 (2.8) 6 (9.8) 0.076 
Arrhythmia 4 (2.4) 1 (0.9) 3 (4.9) 0.140 
Acute kidney injury 2 (1.2) 0 (0.0) 2 (3.2) 0.130 
Acute respiratory distress syndrome 19 (11.4) 2 (1.9) 17 (27.8) <0.001* 
Acute cardiac injury 4 (2.4) 0 (0.0) 4 (6.5) 0.017* 
Clinical outcome 
Died 30 (18.1) 2 (1.9) 28 (45.9) 
<0.001* 
Recovered 136 (81.9) 103 (98.1) 33 (54.1) 
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with statistically significant differences between 
the ICU-admitted patients and non-ICU patients 
(p<0.001, p=0.076 and p=0.017, respectively, Table 
2). Two subjects experienced acute kidney injury; 
both were among the ICU group cases (Table 2). 
The mortality rate was significantly higher in the 
ICU than in non-ICU patients (45.9% vs. 1.9%, 
respectively; p<0.001, Table 2).  
Laboratory data  
There were no substantial differences between the 
two groups in terms of white blood cell counts, 
serum inflammatory indices (C-reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR)), 
and other hematological parameters (Table 3). 
Exceptionally, 19 (32%) patients admitted to the 
ICU had normal platelet counts compared to 46 
(51%) of non-ICU patients (p=0.081, Table 3). 
Regarding biochemistry parameters, significant 
increases in creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH) levels were observed 
in ICU patients compared to non-ICU cases (65% 
and 78% vs. 27% and 57%, p=0.010 and 0.060, 
respectively, Table 3). An elevated level of 
potassium was seen in 25% and 6.9% of ICU and 
non-ICU admitted patients, respectively; while it 
was decreased in 7.0% and 2.3% of ICU-admitted 
and non-ICU patients, respectively (p=0.002, Table 
3).  
Blood saturation indices 
In terms of blood saturation values, PH was 
decreased in 26 (68%) of ICU patients and 15 
(34%) of non-ICU cases (p=0.002, Table 3). 
Moreover, HCo3 was decreased in the former 
group compared with the latter group (76% and  
Table 3: Laboratory findings of pediatric patients with COVID-19 between intensive care unit (ICU)-admitted and non-ICU patients 
Parameters 
Overall (n= 166) Non-ICU (n=105) ICU (n=61) 
P-value 
N (%) 
White blood cell    
0.102 
Decreased 36 (22%) 27 (27%) 9 (15%) 
Increased 23 (14%) 11 (11%) 12 (20%) 
Normal 102 (63%) 63 (62%) 39 (65%) 
Neutrophil    
0.150 
Decreased 19 (12%) 15 (16%) 4 (7.1%) 
Increased 24 (16%) 12 (12%) 12 (21%) 
Normal 109 (72%) 69 (72%) 40 (71%) 
Lymphocyte    
0.106 
Decreased 52 (34%) 38 (39%) 14 (25%) 
Increased 15 (9.7%) 11 (11%) 4 (7.1%) 
Normal 87 (56%) 49 (50%) 38 (68%) 
Hemoglobin    
0.205 
Decreased 68 (44%) 37 (39%) 31 (53%) 
Increased 3 (1.9%) 2 (2.1%) 1 (1.7%) 
Normal 83 (54%) 57 (59%) 26 (45%) 
Platelet    
0.081 
Decreased 27 (18%) 15 (16%) 12 (20%) 
Increased 58 (39%) 30 (33%) 28 (47%) 
Normal 65 (43%) 46 (51%) 19 (32%) 
C-reactive protein    
0.504 Increased 34 (72%) 22 (69%) 12 (80%) 
Normal 13 (28%) 10 (31%) 3 (20%) 
Erythrocyte sedimentation rate   
0.307 Increased 52 (37%) 36 (40%) 16 (31%) 
Normal 89 (63%) 54 (60%) 35 (69%) 
Blood urea nitrogen    
0.208 Increased 35 (23%) 18 (20%) 17 (28%) 
Normal 117 (77%) 74 (80%) 43 (72%) 
Creatinine    
0.061 Increased 70 (46%) 48 (52%) 22 (37%) 
Normal 82 (54%) 44 (48%) 38 (63%) 
Sodium    
0.106 
Decreased 13 (9.0%) 6 (6.9%) 7 (12%) 
Increased 2 (1.4%) 0 (0%) 2 (3.4%) 
Normal 130 (90%) 81 (93%) 49 (84%) 
Potassium    
0.002* 
Decreased 6 (4.2%) 2 (2.3%) 4 (7.0%) 
Increased 20 (14%) 6 (6.9%) 14 (25%) 
Normal 118 (82%) 79 (91%) 39 (68%) 
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 Table 3 (in continue): Laboratory findings of pediatric patients with COVID-19 between intensive care unit (ICU)-admitted and non-
ICU patients 
Parameters 
Overall (n= 166) Non-ICU (n=105) ICU (n=61) 
P-value 
N (%) 
Prothrombin time    
0.070 
Decreased 0 (0%) 0 (0%) 0 (0%) 
Increased 17 (35%) 4 (19%) 13 (46%) 
Normal 32 (65%) 17 (81%) 15 (54%) 
Partial thromboplastin time    
0.506 
Decreased 21 (43%) 8 (38%) 13 (46%) 
Increased 12 (24%) 7 (33%) 5 (18%) 
Normal 16 (33%) 6 (29%) 10 (36%) 
International normalized ratio    
0.082 
Decreased 0 (0%) 0 (0%) 0 (0%) 
Increased 11 (24%) 2 (10%) 9 (35%) 
Normal 35 (76%) 18 (90%) 17 (65%) 
Lactate dehydrogenase    
0.060 
Decreased 2 (2.3%) 1 (1.8%) 1 (3.1%) 
Increased 57 (65%) 32 (57%) 25 (78%) 
Normal 29 (33%) 23 (41%) 6 (19%) 
Creatine phosphokinase    
0.010* 
Decreased 0 (0%) 0 (0%) 0 (0%) 
Increased 22 (42%) 9 (27%) 13 (65%) 
Normal 31 (58%) 24 (73%) 7 (35%) 
Aspartate aminotransferase    
0.801 
Decreased 0 (0%) 0 (0%) 0 (0%) 
Increased 34 (40%) 19 (38%) 15 (42%) 
Normal 52 (60%) 31 (62%) 21 (58%) 
Alanine aminotransferase    
0.406 
Decreased 4 (4.7%) 2 (4.1%) 2 (5.6%) 
Increased 21 (25%) 15 (31%) 6 (17%) 
Normal 60 (71%) 32 (65%) 28 (78%) 
Alkaline phosphatase    
0.999 
Decreased 4 (44%) 3 (43%) 1 (50%) 
Increased 2 (22%) 2 (29%) 0 (0%) 
Normal 3 (33%) 2 (29%) 1 (50%) 
D-dimer    
0.999 Increased 6 (38%) 3 (38%) 3 (38%) 
Normal 10 (62%) 5 (62%) 5 (62%) 
Total Bilirubin    
0.604 Increased 4 (27%) 3 (38%) 1 (14%) 
Normal 11 (73%) 5 (62%) 6 (86%) 
Calcium    
0.306 
Decreased 26 (47%) 14 (54%) 12 (41%) 
Increased 1 (1.8%) 1 (3.8%) 0 (0%) 
Normal 28 (51%) 11 (42%) 17 (59%) 
Phosphorus    
0.900 
Decreased 2 (67%) 2 (67%) 0 (NA%) 
Increased 1 (33%) 1 (33%) 0 (NA%) 
Normal 0 (0%) 0 (0%) 0 (NA%) 
pH    
0.002* 
Decreased 41 (50%) 15 (34%) 26 (68%) 
Increased 5 (6.1%) 5 (11%) 0 (0%) 
Normal 36 (44%) 24 (55%) 12 (32%) 
PCo2    
0.603 
Decreased 35 (43%) 17 (39%) 18 (49%) 
Increased 30 (37%) 18 (41%) 12 (32%) 
Normal 16 (20%) 9 (20%) 7 (19%) 
HCo3    
<0.001* 
Decreased 44 (54%) 16 (36%) 28 (76%) 
Increased 7 (8.6%) 2 (4.5%) 5 (14%) 
Normal 30 (37%) 26 (59%) 4 (11%) 
Po2    
0.501 
Decreased 48 (62%) 26 (60%) 22 (63%) 
Increased 6 (7.7%) 2 (4.7%) 4 (11%) 
Normal 24 (31%) 15 (35%) 9 (26%) 
Base excess    
0.093 
Decreased 46 (73%) 23 (64%) 23 (85%) 
Increased 8 (13%) 5 (14%) 3 (11%) 
Normal 9 (14%) 8 (22%) 1 (3.7%) 
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36%, respectively, Table 3). Lastly, Base Excess 
decrease was more commonly observed in ICU 
compared to non-ICU cases (85% vs. 64%, p=0.093, 
Table 3). 
Radiological features 
Overall, out of the 111 patients who underwent 
chest CT scan, 62 cases (55.8%) showed abnormal 
radiographic appearance. Ground glass opacity 
(n=40; 36.0%), lung consolidation (n=26; 23.4%), 
and pleural effusion (n=10; 9.0%) were the main 
radiological findings (Figure-1). The results of CT 
scans performed on admission showed bilateral 
and unilateral ground glass opacity in 32% and 
7.7% of non-ICU-admitted patients, respectively, 
and 25% and 6.8% of ICU admitted patients, 
respectively (p=0.708). Bilateral and unilateral 
lung consolidation were also observed in 12% and 
6.7% of non-ICU-admitted patients, respectively, 
and 21% and 12% of ICU-admitted patients, 
respectively (p=0.305). Pleural effusion (bilateral 
or unilateral) was found in 5.1% of non-ICU 
admitted patients, and 7% and 2.3% of ICU 
admitted patients, respectively (p=0.804). In ICU 
admitted cases, white lung (unilateral or bilateral) 
were seen in 2.3% of cases and these findings were 
not observed in non-ICU cases (p=0.201) (Figure 
1).  
DISCUSSION 
Iran is considered one of the most affected 
countries by COVID-19 globally, with high 
incidence and mortality rates. To date, several 
studies have reported clinical parameters 
associated with COVID-19 infection in children; 
however, data on pediatric patients in Iran are still 
scarce. On the other hand, there are minimal 
 
Figure 1: Comparisons of major radiological findings between intensive care unit (ICU)-admitted and non-ICU admitted patients 
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published data on pediatric patients requiring ICU 
worldwide. This descriptive cross-sectional 
country-wide investigation compared the 
epidemiologic and clinical features of ICU-admitted 
and non-ICU-admitted pediatric patients with 
confirmed COVID-19 in Iran.  
The present survey showed that malignancies and 
cardiac disorders were the most common 
underlying diseases among ICU-admitted pediatric 
COVID-19 patients. Similar results were found in 
the surveys conducted by Shekerdemian et al. (23) 
and Alfraij et al. (24), where malignancy was the 
most frequent underlying disease among children 
with COVID-19 admitted to ICU. Prata-Barbosa et 
al. and Alfraij et al. also reported that heart disease 
was amongst the most frequent comorbidities 
among COVID-19 pediatric patients admitted to 
ICU (24, 25). According to these results, cancers 
and heart diseases in children were associated with 
increased risk of severe complications of COVID-
19. 
Investigators observed that COVID-19 patients 
with cancer had higher ICU admission rates, severe 
complications, invasive mechanical ventilation, 
and mortality rate compared with COVID-19 
patients without cancer. The higher susceptibility 
of cancer patients to severe COVID-19 infection 
might be explained in part by their systemic 
immunocompromised status induced by the 
underlying malignancy and anticancer therapy. 
Furthermore, most childhood malignancies have 
aggressive behavior and require prolonged periods 
of intensive therapy, which are potentially 
associated with long-term side-effects such as 
severe impairment of innate and adaptive 
immunity (26-28). On the other hand, some other 
studies suggested that children with cancer are not 
more susceptible to severe COVID-19 infection 
than other normal children (12, 28-31). This 
controversy stems, at least in part, from the fact 
that different kinds of cancers have distinct clinical 
features such as different growth rates, different 
responses to treatment, and different prognoses. 
Unfortunately, we were not able to find data about 
the type of tumors in our patients due to the 
retrospective design of our study and so, further 
conclusions cannot be drawn at this stage. 
A portion of ICU-admitted patients were children 
less than five years old. Similar findings were 
reported in two studies conducted by Dong et al. (3, 
10), in which infants and younger children were 
more likely to develop severe clinical 
manifestations of COVID-19 compared with older 
children. A potential explanation for this 
phenomenon might be the immaturity of the 
immune system. The immune system of neonates 
and young children is underdeveloped and 
subdued, which might render them more 
susceptible to most infections, including SARS-
CoV-2. 
Among different clinical symptoms, dyspnea was 
significantly more frequent in pediatric patients 
admitted to ICU than the non-ICU patients. This 
finding was consistent with the result of a survey 
conducted in New York City (32). As reported, 
dyspnea was the only clinical symptom, which was 
significantly more frequent in pediatric patients 
admitted to the ICU than those admitted to the 
medical wards (92.3% vs. 30.3%, respectively). 
Similar results were obtained in the study 
conducted by Bhumbra et al. (33), where 71% and 
58% of pediatric COVID-19 patients admitted to 
the ICU and general ward presented dyspnea, 
respectively. Thus, it seems that in most cases, the 
severe form of COVID-19 in children might be 
associated with lung involvement. This 
interpretation is supported by another finding: 
ARDS rate was substantially higher in patients 
admitted to the ICU (27.8%) than those who were 
not admitted to the ICU (1.9%). Moreover, Chao et 
al. reported that the rate of ARDS was higher in 
patients admitted to the ICU (76.9%) compared 
with patients admitted to the medical unit (0%) 
(32). The present survey showed that acute cardiac 
injury and acute kidney injury cases were only seen 
among ICU-admitted patients. In parallel, Stewart 
et al. reported that most acute kidney injury cases 
(93%) were found in those admitted to the 
pediatric ICU (34). Chao et al. also showed a 
significantly higher rate of acute kidney injury 
among pediatric patients admitted to the ICU than 
non-ICU patients (38.5% vs. 0%, respectively) (32). 
It has been reported that heart failure and acute 
cardiac injury are significantly associated with in-
hospital death (35). Alfraij et al. also reported that 
circulatory failure was significantly associated with 
pediatric death in their cohort study (24). Taken 
together, these findings indicate that acute cardiac 
injury and acute kidney injury are associated with 
severe COVID-19 among children. 
The present investigation showed that with the 
exception of few blood test parameters, 
abnormalities, and also some atypical blood 
saturation indices, the differences in the rest of 
laboratory test results were not significant 
between the ICU and non-ICU individuals. These 
findings shed important light on the nature of the 
disease in this population. Unlike in the adults, it 
seems that no significant laboratory parameters 
could be characterized for the prognosis of COVID-
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19 clinical outcomes in pediatrics.  
Limitations 
This study was limited to a small number of 
patients. In fact, the preliminary number of study 
population was shrunk from 325 to 166 due to the 
unavailability of molecular test results at the 
beginning of the epidemic in the country. 
Therefore, we only analyzed the data of patients 
who were positive for SARS-Cov-2 on RT-PCR. 
Second, all the laboratory assays were performed 
as routine tests. Hence, we were not able to assess 
other medical conditions based on the specific 
laboratory tests.  
CONCLUSIONS 
In conclusion, this multicenter study demonstrates 
that underlying diseases were the major 
contributing factors to increased ICU admissions 
and mortality rates in pediatric COVID-19 patients. 
There are few paraclinical parameters for 
differentiating pediatrics in terms of prognosis and 
serious outcomes of COVID-19. Our findings 
emphasize that healthcare providers should 
consider children as a high-risk group, especially 
those with younger age and underlying medical 
conditions, and define strategies to control and 
prevent COVID-19 transmission in this population. 
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